NCT00835042View on ClinicalTrials.gov

Moexipril HCL/Hydrochlorothiazide 15/25 mg Tablets Under Fasting Conditions

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

November 30, 2003

Study Completion Date

November 30, 2003

Conditions
Healthy
Interventions
DRUG

Moexipril HCl/hydrochlorothiazide 15/25 mg tablets

1 x 15/25 mg

DRUG

UNIRETIC® 15/25 mg tablets

1 x 15/25 mg

Trial Locations (2)

63301

Gateway Medical Research, Inc., Saint Charles

77099

Bioassay Laboratory, Inc., Houston

All Listed Sponsors
lead

Teva Pharmaceuticals USA

INDUSTRY

NCT00835042 - Moexipril HCL/Hydrochlorothiazide 15/25 mg Tablets Under Fasting Conditions | Biotech Hunter | Biotech Hunter